CNS Pharmaceuticals, Inc. - Common Stock (CNSP)

A recent study has found that patients diagnosed with glioblastoma, a deadly brain cancer, can have extended survival durations if they receive an mRNA Covid-19 shot not more than 100 days before they undergo surgery to remove the tumor.

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor “Why Now” on-demand conference, where President and CEO Rami Levin discussed the company strategic transformation. Levin highlighted CNS Pharmaceuticals newly assembled executive leadership team, enhanced financial position following its recent financing and disciplined approach to evaluating differentiated assets as the company works to generate long-term growth and value.

Video webcast now available here

Recurrent glioblastoma leaves patients with almost no effective treatments to fall back on. Standard therapies typically combine surgery with chemotherapy, but the disease usually comes back in a harsher, harder-to-treat form.

Glioblastoma is very difficult to treat because it quickly adapts and evolves to become resistant to existing treatments indicated for brain cancers. Now, scientists have found a protein on this cancer’s cells that could be targeted in order to make the cancer more vulnerable to the treatments administered to combat this deadly malignancy.

CNS Pharmaceuticals (NASDAQ: CNSP), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, reported second-quarter 2026 results and provided an update on the corporate strategy introduced in March. Cash and cash equivalents totaled approximately $20 million at June 30, up from $7.2 million at Dec. 31, 2025, primarily reflecting a May private placement that generated approximately $22.5 million in gross proceeds. The company reported a second-quarter net loss of approximately $2.6 million, or $0.37 per basic and diluted share, compared with a net loss of approximately $2.4 million, or $6.42 per basic and diluted share, a year earlier. Research and development expenses remained approximately $1.2 million while general and administrative expenses increased to approximately $1.5 million from $1.2 million.

A clinical trial has found that placing radioactive tiles into the brain cavity at tumor removal dramatically cuts recurrence and extends survival. The ROADS trial, led by MD Anderson Cancer Center, was presented at the 2026 American Society of Clinical Oncology meeting.

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline

Scientists at the University of Virginia have discovered that deadly brain tumors may be more susceptible to focused ultrasound than previously thought. Research conducted at the university’s Focused Ultrasound Cancer Immunotherapy Center found that cancer drugs delivered via sound waves could be more effective in treating gliomas than conventional brain cancer treatments.

Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and was treated as such, but additional tests brought to light a scarier cause of his illness: cysts resulting from a pork tapeworm infection. This case highlights the dangers of exposure to these worms, or eating pork that hasn’t been cooked fully.

Glioblastoma multiforme (GBM) is the deadliest type of brain cancer and patients usually die within 15 months from the time they are diagnosed with the malignancy. Existing treatments like surgery, chemotherapy and radiotherapy aren’t effective in halting the progression of this disease. Now, a new study shows that an experimental therapy containing vitamin B12 could halt GBM in its tracks .

Research published in the journal Nature Medicine has revealed that experimental immunotherapy may provide some relief to patients with aggressive pediatric cancers. Spinal cord and brain tumors tend to have the most detrimental effects on pediatric patients, but current treatment protocols often have low success rates.

For a long time, many people have claimed that using a mobile phone can cause brain cancer. These fears were so widespread that the World Health Organization commissioned teams to conduct 13 reviews aimed at establishing whether electromagnetic waves, such as those that enable mobile phones to work, had any health effects. The reviews were commissioned back in 2019.

A research team investigating children’s brain tumors has found promising results combining a hormone treatment with standard chemotherapy protocols . Triiodothyronine, commonly called T3, is a medication long used to manage thyroid disorders in patients throughout the lifespan. The hormone showed enhanced effectiveness when added to conventional cancer therapy in laboratory studies and animal models.

Traditionally, vaccines have been used as a way to prevent many diseases, such as the childhood vaccines used to prevent measles. However, scientists are now developing therapeutic vaccines that can be given to cancer patients in order to slow or reverse the progression of the malignancy. One such vaccine was recently developed in Germany and the results offer cautious hope for patients with deadly brain tumors.

Researchers from King’s College London and McMaster University have made a discovery that could fundamentally change how doctors treat brain cancer. The team identified a molecular pathway that appears critical to cancer’s ability to migrate to the brain.

Researchers at Washington University (WashU) Medicine have conducted a small clinical trial testing a new vaccine against glioblastoma . The formulation was administered to nine patients who had undergone surgery and chemo-radiation therapy to remove their tumors. The results of this study show promise in extending tumor-free survival for a disease that is currently hard to treat.

A study conducted by a team at Mass General Brigham has found that people with a history of traumatic brain injury had a higher chance of dying as a result of brain cancer. The findings create an urgency to rethink how TBI cases are handled not just in the immediate aftermath but also over the long term.

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in a virtual investor segment featuring Chief Financial Officer Steve O’Loughlin, who discussed the company’s recently completed oversubscribed $22.5 million financing. The presentation focused on the factors supporting the successful capital raise following CNS Pharmaceuticals’ strategic reset and acquisition-focused transformation.

Access the segment here

Scientists have identified a potential mechanism through which aggressive pediatric brain tumors called diffuse midline gliomas spread. The researchers found that immune cells within the brain, called microglia, produce proteins called fibronectin that help the tumors to progress.

A new doctoral study from Sweden’s Karolinska Institutet has found that sexual difficulties are common among young people who have survived cancer treatment . The nature and severity of those difficulties shift considerably based on cancer type and how intensively the patient was treated. Charlotta Bergström, a nurse and doctoral student at the Karolinska Institutet, led the research, which covered more than 1,000 patients.

A new doctoral study from Sweden’s Karolinska Institutet has found that sexual difficulties are common among young people who have survived cancer treatment . The nature and severity of those difficulties shift considerably based on cancer type and how intensively the patient was treated. Charlotta Bergström, a nurse and doctoral student at the Karolinska Institutet, led the research, which covered more than 1,000 patients.

Researchers at the University of Virginia have conducted a study that offers new insights into what happens when there are errors in the process of brain cells dividing to form new cells as the brain is growing. Their findings could open the door to treating cancer and many developmental disorders of the brain.